Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jun 15, 2022 9:01pm
180 Views
Post# 34760042

The floodgates for massive dilution has been fully opened.

The floodgates for massive dilution has been fully opened.Warrants on steroids on the CSE. Nothing about an uplist to NASDAQ has changed the landscape of fire sale shares at all time lows. Moreau will have Algernon Pharmaceuticals diluted back to 100+ Million shares in record time. The dilution scheme continues as your shares have been cut by 100 to 200 times since Moreau took the job in 2018. Failures at every time remains his tracker it's going back more than a decade since his days at Miraculins. The Miraculins wrecking crew now runs Algernon Pharmaceuticals from top to bottom I'd expect Kulwant Malhi to be part of 5he offering and expect the dog cr@p to be flipped out of shares once again. Moreau actually told shareholders a move to NASDAQ was necessary ong with the 100 to 1 reverse split. How? The sh!t moves look to be the same as before. Just this time you have multiple clinical trials starting at Phase 1 versus Phase 2. Count those decisions as your fast track to 100+ Million shares fly diluted. Moreau aims he wants to change lives of shareholders significantly. That he has done and continues to do with his leadership skill or lack thereof. He has not proven he's capable of running a successful publicly traded company in any significant way. The only true winners ever invested in the company is insiders/pp & warrant holders/fam n friends. Maybe the BioPub Clan as well. Lots and lots more pain is coming to shareholders sooner rather than later. Algernon Pharmaceuticals is a laughing-stock at best.
<< Previous
Bullboard Posts
Next >>